PATIENTS WITH EBV+ PTLD MAY REQUIRE YOU TO CHART A DIFFERENT COURSE

EBV+ PTLD IS AN UNPREDICTABLE THREAT FOR TRANSPLANT RECIPIENTS

Post-transplant lymphoproliferative disease (PTLD) is a lymphoid and/or plasmacytic proliferation that occurs as a result of immunosuppression in a setting of solid organ or allogeneic hematopoietic cell transplantation. PTLD can be Epstein-Barr virus (EBV) positive or EBV negative.1

Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) is a rare, acute, and potentially life-threatening lymphoma that presents challenges in the management of transplant patients.2 Staying connected to the latest scientific information, treatment guidelines, and useful resources about EBV+ PTLD can help you provide the best possible care for your patients.

Learn more about:

Vigilantly monitoring patients for signs and symptoms

Understanding monitoring and clinical presentation

Follow the latest transplant-specific guidelines when initiating treatment

WHICH PATIENTS ARE MOST AT RISK FOR DEVELOPING EBV+ PTLD?

Solid organ transplant and EBV+ PTLD
Hematopoietic cell transplant (HCT) and EBV+ PTLD Hematopoietic cell transplant (HCT) and EBV+ PTLD

Solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients have unique sets of risk factors for the development of EBV+ PTLD.

EBV+ PTLD: A “MAN-MADE” COMPLICATION OF TRANSPLANT

Dr Ran Reshef, MD, Columbia University

EBV+ PTLD video – Dr Reshef
Healthy B cell
Epstein-Barr virus
Epstein-Barr virus
Epstein-Barr virus
Epstein-Barr virus
Epstein-Barr virus
Epstein-Barr virus

Post-transplant primary infection or viral reactivation

B cell

Epstein-Barr virus

EBV+ PTLD IS A RARE, ACUTE, AND POTENTIALLY DEADLY LYMPHOMA

It is a direct consequence of EBV-infected B-cell proliferation in patients with suppressed and/or depleted T cells.2

Featured Resources

Dr Mohty
EBV+ PTLD Risk Factors
in HCT Patients
01:06
EBV+ PTLD
00:47
Clinical Transplantation article: Post‐transplant Lymphoproliferative Disorders, Epstein‐Barr Virus Infection, and Disease in Solid Organ Transplantation

UD Allen, JK Preiksaitis

Post‐transplant Lymphoproliferative Disorders, Epstein‐Barr Virus Infection, and Disease in Solid Organ Transplantation

Clinical Transplantation
2019;33(9):e13652

References

1. Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173-183. 2. Dierickx D, Habermann TM. Post-transplantation lymphoproliferative disorders in adults. N Eng J Med. 2018;378(6):549-562.